Desmoda oral solution is now FDA-approved for central diabetes insipidus, allowing clinicians to tailor dosing to individual water balance patterns.

The Tennessee Poison Center is seeing a sharp increase in calls related to tirzepatide and semaglutide exposure over the last ...

All of the guys that I have been emotionally attracted to have been busts in the past. I am not looking for anything serious, but I would like to have a good time with someone who can put some effort ...

Apellis Pharmaceuticals (NASDAQ:APLS) used its fourth-quarter and full-year 2025 earnings call to highlight what management ...

AUSTIN, TX / ACCESS Newswire / March 2, 2026 / In modern metabolic medicine, few treatments have reshaped care like GLP-1 receptor agonists. If you are asking what is semaglutide, it is a prescription ...

Full-year 2025 net product revenues of $689 million SYFOVRE® (pegcetacoplan injection) full year 2025 net product revenue of $587 millionEMPAVELI® (pegcetacoplan) full year 2025 net product revenue of ...

Research supports the safety and efficacy of compounded lidocaine plus epinephrine for up to 24 hours at room temperature and ...

ZYNRELEF® and APONVIE® Drive 65% Year-Over-Year Net Revenue Growth in Acute Care Franchise– Achieved $154.9 Million in 2025 Net Revenue– Issues ...

Walk into a Florida med spa for a lunchtime Botox injection and you may feel reassured by a framed certificate on the wall touting the provider’s board certification in aesthetics, or by the master ...

Executive SummaryThe global pharmaceutical drug delivery sector operates as a central pillar within the broader life sciences industry. As treatment protocols shift from conventional dosing toward ...

Drive 65% Year-Over-Year Net Revenue Growth in Acute Care Franchise- Achieved $154.9 Million in 2025 Net Revenue- Issues Full-Year 2026 Net Revenue Guidance of $173 to $183 ...